Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Why should you always consult your Pharmacist or Doctor?
Mohamad Ali Salloum, PharmD • January 25, 2022
Share
Some times we underestimate the symptoms that we are suffering from and choose to diagnose and heal ourselves by looking up the symptoms online.
This is one of the mistakes that people do frequently to avoid going to the physician or the pharmacist to save time. (As they may consider)
I’m not going to lie to you, sometimes you may get the diagnosis and the treatment right by searching online, however, most of the times the internet just exaggerate the signs and symptoms and makes you think that you have a serious illness that can’t be cured unless you drink a special syrup that makes you immortal :) (Disclaimer: there is no such thing)
Back to our topic.
I will list some cases where when you don’t consult a health care professional you might end up hurting yourself irreversibly.
Case 1:
A patient that has elevated blood pressure (Hypertension) and has some inflammation where he takes anti-inflammatory drugs.
Case 2:
A patient that takes antibiotics whenever he/she has respiratory infection.
Case 3:
A patient with elevated blood pressure (Hypertension) with a kidney dysfunction that is already taking ACE-inhibitor (Angiotensin-converting enzyme- inhibitor) and decides to start taking Potassium Supplements for a certain reason.
If you are a health care professional reading the above cases, I guess you already detected the problems in these cases. If not, I will list the scenarios that might happen in the worst cases.
Case 1 Scenario:
Anti-inflammatory drugs especially the NSAIDs (non-steroidal anti-inflammatory drugs) have antagonistic effects when administered with anti-hypertensive drugs(1). When taken chronically, these NSAIDs will lead to un-controlled hypertension. The solution for this case is to take an anti-inflammatory drug that has the lowest effect on the hypertension and for a short time. It is better to be discontinued if its use is not necessary.
Case 2 Scenario:
Taking antibiotics randomly and without confirming their necessity will lead to antibiotic resistance within the individual which will allow later simple infections to become lethal and hard to get rid of. Before taking any antibiotic, the pharmacist or physician should be consulted to assess their necessity. (2)
Case 3 Scenario:
ACE-inhibitors already lead to increased blood levels of Potassium. Administering Potassium Supplements with ACE-inhibitors will lead to hyperkalemia and thus arrhythmias and other symptoms (3). The best practice in this case is to always monitor the levels of potassium, and if the Potassium Supplement is not necessary it’s better to discontinue its use. For hypertensive patients with normal kidney function, there is a study concluded that an increase in dietary potassium over a 4 week period is safe (4).
Resources:
(1)Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. DOI: 10.1111/fcp.12014
(2)The growing burden of antimicrobial resistance. DOI: 10.1093/jac/dkn241
(3)Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed DOI: 10.1016/j.ajem.2010.08.029
(4)Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system. DOI: 10.3945/ajcn.115.129635
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Why does this always happen?
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.